Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
Cytokine Growth Factor Rev
; 54: 43-50, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-634065
ABSTRACT
Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) - mainly IFN-α and ß -represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Interferon-beta
/
Interferon-alpha
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Cytokine Growth Factor Rev
Journal subject:
Allergy and Immunology
/
Biochemistry
Year:
2020
Document Type:
Article
Affiliation country:
J.cytogfr.2020.07.010
Similar
MEDLINE
...
LILACS
LIS